Half year 2020 results

Transformational performance set to continue Paris, France and Camberley, UK – 17 September 2020 – Novacyt (ALTERNEXT: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its unaudited results for the six months ended 30 June 2020 and provides an update on its growth strategy. http://novacyt.com/wp-content/uploads/2020/09/Novacyt-Interim-Results-to-June-2020-17.09.20-ENGLISH.pdf  Visit Page

Appointment of Joint Broker

Paris, France and Camberley, UK – 16 September 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, is pleased to announce the appointment of Numis Securities Limited as Joint Broker to the Company with immediate effect. http://novacyt.com/wp-content/uploads/2020/09/Novacyt-Appointment-of-Joint-Broker.pdf

Visit Page

Launch of two gene COVID-19 test

Paris, France and Camberley, UK – 4 September 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that, further to the announcement on 27 July 2020, the Company has launched a CE-Mark approved polymerase chain reaction (PCR) two gene target test for COVID-19. http://novacyt.com/wp-content/uploads/2020/09/Novacyt-launch-of-2-gene-COVID-19-test-ENG.pdf

Visit Page